Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

119 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes.
Rouzier R, Extra JM, Klijanienko J, Falcou MC, Asselain B, Vincent-Salomon A, Vielh P, Bourstyn E. Rouzier R, et al. J Clin Oncol. 2002 Mar 1;20(5):1304-10. doi: 10.1200/JCO.2002.20.5.1304. J Clin Oncol. 2002. PMID: 11870173
Patients' preference of trastuzumab administration (subcutaneous versus intravenous) in HER2-positive metastatic breast cancer: Results of the randomised MetaspHer study.
Pivot X, Spano JP, Espie M, Cottu P, Jouannaud C, Pottier V, Moreau L, Extra JM, Lortholary A, Rivera P, Spaeth D, Attar-Rabia H, Benkanoun C, Dima-Martinez L, Esposito N, Gligorov J. Pivot X, et al. Among authors: extra jm. Eur J Cancer. 2017 Sep;82:230-236. doi: 10.1016/j.ejca.2017.05.009. Epub 2017 Jun 23. Eur J Cancer. 2017. PMID: 28648618 Clinical Trial.
[[How to finance chemotherapy with new cancer drugs?].
Livartowski A, Beuzeboc P, Le Vu B, Courbard M, Pierga JY, Extra JM, Scholl S, Pouillart P. Livartowski A, et al. Bull Cancer. 2000 Oct;87(10):745-54. Bull Cancer. 2000. PMID: 11084538 French.
[Promising results of bimonthly chemotherapy with high dose cyclophosphamide and epirubicin in induction treatment of inflammatory cancer of the breast].
Culine S, Extra JM, Espie M, Bourstyn E, Dieras V, Giacchetti S, Maylin C, De Rocquancourt A, Morvan F, Marty M. Culine S, et al. Bull Cancer. 1993 Nov;80(11):994-1000. Bull Cancer. 1993. PMID: 8081037 French.
High-dose sequential epirubicin and cyclophosphamide with peripheral blood stem cell support for advanced breast cancer: results of a phase II study.
Cottu PH, Extra JM, Espie M, Marolleau JP, de Roquancourt A, Makke J, Miclea JM, Laurence V, Mayeur D, Lerebours F, Cuvier C, Marty M. Cottu PH, et al. Br J Cancer. 2001 Nov 2;85(9):1240-6. doi: 10.1054/bjoc.2001.2069. Br J Cancer. 2001. PMID: 11720455 Free PMC article. Clinical Trial.
Primary chemotherapy for operable breast cancer: incidence and prognostic significance of ipsilateral breast tumor recurrence after breast-conserving surgery.
Rouzier R, Extra JM, Carton M, Falcou MC, Vincent-Salomon A, Fourquet A, Pouillart P, Bourstyn E. Rouzier R, et al. J Clin Oncol. 2001 Sep 15;19(18):3828-35. doi: 10.1200/JCO.2001.19.18.3828. J Clin Oncol. 2001. PMID: 11559720
Response to chemotherapy is a major parameter-influencing long-term survival of metastatic breast cancer patients.
Pierga JY, Robain M, Jouve M, Asselain B, Diéras V, Beuzeboc P, Palangié T, Dorval T, Extra JM, Scholl S, Pouillart P. Pierga JY, et al. Ann Oncol. 2001 Feb;12(2):231-7. doi: 10.1023/a:1008330527188. Ann Oncol. 2001. PMID: 11300330 Clinical Trial.
Predictive factors of response to first-line chemotherapy in 1426 women with metastatic breast cancer.
Robain M, Pierga JY, Jouve M, Asselain B, Diéras V, Beuzeboc P, Palangié T, Dorval T, Extra JM, Scholl S, Pouillart P. Robain M, et al. Eur J Cancer. 2000 Dec;36(18):2301-12. doi: 10.1016/s0959-8049(00)00325-7. Eur J Cancer. 2000. PMID: 11094303
Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer.
Pierga JY, Mouret E, Diéras V, Laurence V, Beuzeboc P, Dorval T, Palangié T, Jouve M, Vincent-Salomon A, Scholl S, Extra JM, Asselain B, Pouillart P. Pierga JY, et al. Br J Cancer. 2000 Dec;83(11):1480-7. doi: 10.1054/bjoc.2000.1461. Br J Cancer. 2000. PMID: 11076657 Free PMC article.
119 results
Jump to page
Feedback